Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bupropion/naltrexone - Currax Pharmaceuticals

Drug Profile

Bupropion/naltrexone - Currax Pharmaceuticals

Alternative Names: Bupropion/naltrexone; Contrave; Mysimba; Naltrexone HCl/ bupropion HCl prolonged release; Naltrexone HCl/bupropion HCl; Naltrexone HCl/bupropion HCl extended release; Naltrexone SR/bupropion SR; Naltrexone XR/bupropion XR; Naltrexone/bupropion; NB32

Latest Information Update: 03 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Orexigen Therapeutics
  • Developer Bausch Health Companies; Biologix FZCo; Kwang Dong Pharmaceutical; Orexigen Therapeutics; Rovi
  • Class Analgesics; Antidepressants; Drug withdrawal therapies; Irritable bowel syndrome therapies; Morphine derivatives; Obesity therapies; Propiophenones; Small molecules; Smoking cessation therapies
  • Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Opioid mu receptor antagonists; Opioid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Obesity

Highest Development Phases

  • Marketed Obesity
  • No development reported Depressive disorders; Smoking withdrawal

Most Recent Events

  • 27 Sep 2019 Nalpropion Pharmaceuticals has been acquired and merged into Currax Pharmaceuticals
  • 30 Apr 2019 Currax Pharmaceuticals acquired all the assets of Pernix Therapeutics ,
  • 19 Dec 2018 Orexigen Therapeutics expands agreement with iNova Pharmaceuticals for commercialisation of naltrexone/bupropion in Southeast Asia, the Pacific, Australia, New Zealand and South Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top